CLINICAL TRIALS PROFILE FOR PRASTERONE
✉ Email this page to a colleague
All Clinical Trials for PRASTERONE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00006219 ↗ | Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma | Completed | National Cancer Institute (NCI) | Phase 2 | 2000-08-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma. |
| NCT00006219 ↗ | Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma | Completed | Mayo Clinic | Phase 2 | 2000-08-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma. |
| NCT00082511 ↗ | GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids | Completed | Genelabs Technologies | Phase 3 | 2003-07-01 | Open label safety and efficacy follow-up. |
| NCT00310791 ↗ | Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2/Phase 3 | 2004-04-01 | This study seeks to gain new information on why young women with anorexia nervosa are predisposed to early bone loss and osteoporosis. Through a randomized treatment trial in which participants will receive either combined therapy with the adrenal hormone, dehydroepiandrosterone (DHEA) and estrogen replacement therapy or placebo, we will determine the effects of an 18-month treatment course on bone mass, circulating markers of bone turnover, and serum levels of a factor, insulin-like growth factor I (IGF-I). We are also studying if these therapies change bone structure to increase skeletal strength compared to placebo, as assessed through cross-sectional geometric analysis of our bone density data by dual-energy x-ray absorptiometry (DXA). |
| NCT00310791 ↗ | Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa | Completed | United States Department of Defense | Phase 2/Phase 3 | 2004-04-01 | This study seeks to gain new information on why young women with anorexia nervosa are predisposed to early bone loss and osteoporosis. Through a randomized treatment trial in which participants will receive either combined therapy with the adrenal hormone, dehydroepiandrosterone (DHEA) and estrogen replacement therapy or placebo, we will determine the effects of an 18-month treatment course on bone mass, circulating markers of bone turnover, and serum levels of a factor, insulin-like growth factor I (IGF-I). We are also studying if these therapies change bone structure to increase skeletal strength compared to placebo, as assessed through cross-sectional geometric analysis of our bone density data by dual-energy x-ray absorptiometry (DXA). |
| NCT00310791 ↗ | Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa | Completed | Boston Children's Hospital | Phase 2/Phase 3 | 2004-04-01 | This study seeks to gain new information on why young women with anorexia nervosa are predisposed to early bone loss and osteoporosis. Through a randomized treatment trial in which participants will receive either combined therapy with the adrenal hormone, dehydroepiandrosterone (DHEA) and estrogen replacement therapy or placebo, we will determine the effects of an 18-month treatment course on bone mass, circulating markers of bone turnover, and serum levels of a factor, insulin-like growth factor I (IGF-I). We are also studying if these therapies change bone structure to increase skeletal strength compared to placebo, as assessed through cross-sectional geometric analysis of our bone density data by dual-energy x-ray absorptiometry (DXA). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PRASTERONE
Condition Name
Clinical Trial Locations for PRASTERONE
Trials by Country
Clinical Trial Progress for PRASTERONE
Clinical Trial Phase
Clinical Trial Sponsors for PRASTERONE
Sponsor Name
